Hong Kong
· Delayed Price · Currency is HKD PegBio Company Description
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China.
The company’s products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of T2DM and obesity; and PB-201, a candidate for the treatment of T2DM.
The company’s PB-718 that is in Phase IIb clinical trials for the treatment non-alcoholic lipids fatty liver disease; and PB-1902 that is in phase II clinical trials for the treatment of opioids constipation and obesity.
It is also developing GLP-1 for use in the treatment of Alzheimer’s disease; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia.
Additionally, it is also conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide and PB-2309, a GLP-1/GIP/GCG triple receptor agonist for the treatment of T2DM, NASH, and obesity.
The company was incorporated in 2008 and is based in Hangzhou, China.
| Country | China |
| Founded | 2008 |
| Industry | Drugs, Drug Proprietaries, and Druggists' Sundries |
| Employees | 53 |
| CEO | Min Xu |
Contact Details
Address: Room 606 Hangzhou, 215123 China | |
| Phone | 86 512 6295 6128 |
| Website | pegbio.com |
Stock Details
| Ticker Symbol | 2565 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 5122 |
Key Executives
| Name | Position |
|---|---|
| Min Xu | Chief Executive Officer |
| Xiaojun Wang | Chief Financial Officer |